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Abstract: After the increasing rate of deaths observed during the 1980s due to human 
immunodeﬁ  ciency virus (HIV) infection, the health-related quality of life and life expectancy of 
persons with hemophilia have improved, mainly due to the progresses of replacement therapy and 
antiviral drugs and to the improvement of the global comprehensive care provided by specialized 
centers. As a consequence, an increasing number of hemophiliacs have reached an older age 
and nowadays physicians in hemophilia centers ﬁ  nd that they must handle age-related clinical 
problems never previously observed in this population. The management of elderly persons 
with congenital hemophilia is discussed in the ﬁ  rst part of this review. The second part describes 
the general aspects of acquired hemophilia due to anti-factor VIII autoantibodies, focusing on 
the clinical management of elderly patients, one of the groups most frequently affected by this 
acquired bleeding disorder.
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Introduction
Since the early 1970s there have been dramatic improvements in the availability and 
quality of treatment for persons with hemophilia (Mannucci and Tuddenham 2001). 
As a result of this progress, barring the consequences of the human immunodeﬁ  ciency 
virus (HIV) epidemics in the 1980s, the life span of hemophiliacs has progressively 
become similar to that of males in the general population, at least in more developed 
countries (Mejia-Carvajal et al 2006). Accordingly, a considerable number of hemo-
philiacs now reach old age: in Italy, for instance, nearly 8% of persons with severe 
hemophilia A or B are 65 years old or older (Tagliaferri et al 2006). However, with 
age, persons with hemophilia develop medical and surgical diseases (eg, cardiovascu-
lar diseases, prostatic hypertrophy, cancers, renal disease) not previously seen in this 
group. This aspect, together with the management of these patients, is discussed in 
the ﬁ  rst part of this review. The second part addresses the main features and clinical 
management of acquired hemophilia due to anti-factor VIII antibodies, an acquired 
disease that may occur in elderly people.
Management of congenital hemophilia 
in the elderly
Life-expectancy, causes of death and quality of life
A number of studies have analyzed life expectancy and causes of death in hemophiliacs. 
However, the vast majority of them have evaluated only subgroups of patients, not the 
whole population. The mortality of patients infected by the hepatitis C virus (HCV) or 
HIV has been specially analyzed. For example, Darby et al (1997) analyzed mortality 
in hemophiliacs in the United Kingdom infused with blood products contaminated 
with HCV. Other studies evaluated the mortality rate among HIV-infected patients 
in Spain (del Amo et al 2006), the United Kingdom (Darby et al 2004a) and Canada 
(Arnold et al 2006). Finally, another study investigated the effect of factor VIII and 
IX inhibitors on mortality in a hemophilia population (Darby 2004b).Clinical Interventions in Aging 2007:2(3) 362
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Although only a small number of studies have so far 
evaluated mortality in the whole population of hemophiliacs 
(Street et al 2006), these are interesting because they cover 
the whole history of the clinical-therapeutic approach to 
hemophilia, from the dramatic increase in life expectancy 
between the 1940s and 1980s with the advent of replace-
ment therapy with plasma-derived clotting factor to the 
catastrophic contamination of the plasma pool by HIV and 
HCV in the 1980s (Street et al 2006). In parallel with the 
therapeutic progresses, the causes of death have changed 
in hemophilia, hemorrhage being replaced by the acquired 
immunodeﬁ  ciency syndrome (AIDS) as the leading cause 
of death (Mejia-Carvajal et al 2006). Indeed, the mortality 
curve in hemophiliacs over the years has a biphasic form 
with two peaks: one before the 1960s (before the widespread 
availability of factor replacement therapy) and the other in 
the 1980s–1990s (after the occurrence of AIDS and of the 
clinical manifestations of earlier HCV infections). This trend 
has been conﬁ  rmed by a recent survey that analyzed the 
mortality rate and causes of death in 967 Dutch hemophiliacs 
(Plug et al 2006). During the period of the study (1992–2001) 
the mortality rate was 2.3 times higher in patients with 
hemophilia than in the general male population. Moreover, 
comparing these data with those previously reported by the 
same group (Rosendaal et al 1989; Triemstra et al 1995), the 
life expectancy of patients with severe hemophilia decreased 
from 63 years in the period 1973–1986 to 61 and 59 years in 
the period 1986–1992 and 1992–2001, respectively. How-
ever, the exclusion of virus-related deaths resulted in a life 
expectancy at birth of 74 years, similar to that of the unaf-
fected Dutch male population. Similar trends were observed 
in studies involving Scottish (Ludlam 2000) and Canadian 
(Walker 1998) hemophiliacs. From 1900 to 1942 the life 
expectancy of severe hemophiliacs in Sweden was 16.5 years; 
this increased to 23.2 years between 1943 and 1957 (Ramgren 
1962) and to 50 years between 1957 and 1980 (Larsson and 
Wiechel 1983). For comparison, the life expectancy of unaf-
fected Swedish men during the latter period was 75 years. 
Another study analyzed 163 patients with severe hemophilia 
A living in Finland in the period between 1930–79 (Ikkala 
1982). During 50 years of observation, the mean age at 
death increased from 7.8 years in 1930–39 to 25.5 years in 
1970–79. The effect of HIV infection on age and causes of 
death among persons with hemophilia A was analyzed in a 
study conducted in the United States (Chorba et al 2001). The 
median age at death decreased from 55 years in 1979–1982 
to 40.5 years in 1987–1990 and increased to 46 years in 
1995–1998, although the median age at death of patients with 
hemophilia A and HIV-related disease in the latter period was 
33 years, compared to 72 years for those without HIV-related 
disease. During the same period, hemophilia A-associated 
deaths decreased by 41%, with a 78% decrease among those 
who had HIV-related disease. This decline in HIV mortality 
was consistent with that observed in the general popula-
tion of HIV-infected persons and reﬂ  ected improvements 
in anti-retroviral therapy. On the other hand, another study 
that analyzed the causes of death among hemophiliacs not 
infected by HIV found that the leading cause of death was 
hemorrhage, followed by liver disease (hepatitis C and B), 
stroke and cancer. Table 1 summarizes the literature data on 
outcomes in hemophilia patients.
Currently, children with hemophilia look forward 
to a normal life expectancy and excellent health-related 
quality of life (Gringeri et al 2006). The most important 
Table 1 Analysis of the literature data on life expectancy of persons with hemophilia
  Life expectancy (years)
  Severe hemophiliacs  Unaffected males
Author  Country  Period of the study  All patients  HIV–
Rosendaal et al 1989  Nederland  1973–1986  63  –  71
Triemstra et al 1995  Nederland  1986–1992  61  –  74
Plug et al 2006  Nederland  1992–2001  59  74  76
Ramgren 1962  Sweden  1900–1942  16.5  –  –
   1943–1957  23.2  –  75
Larsson and Wiechel 1983  Sweden  1957–1980  50  –  75
Walker and Julian 1998  Canada  1980–1995  47.4  73  –
Ikkala et al 1982  Finland  1930–1939  7.8  –  –
   1970–1979  25.5  –  – 
Chorba et al 2001  USA  1979–1982  55  –  –
   1987–1990  40.5  –  –
   1995–1998  46  72  –
Abbreviations: HIV, human immunodeﬁ  ciency virus.Clinical Interventions in Aging 2007:2(3) 363
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factors contributing to the improved quality of life, reduced 
morbidity and increased life expectancy are the availability 
for replacement therapy of high-quality factor concen-
trates (ie, virus inactivated plasma-derived clotting factor 
concentrates and recombinant products), insights into the 
management of hemophilic arthropathy and liver disease 
(ie, surveillance of patients with chronic hepatitis, especially 
with respect to cancer and liver failure, and newer treat-
ment options such as antiviral treatment against HIV and 
HCV and liver transplantation) and the improved medical 
management provided by specialized hemophilia treatment 
centers. High-quality factor concentrates are important not 
only for reducing the likelihood of death from hemorrhage 
but also for improving the quality of life, especially through 
prophylactic regimens and home treatment. Secondary pro-
phylaxis, in particular, is becoming frequently prescribed 
among hemophiliacs, although only few data are available in 
this setting (Tagliaferri et al 2006a). The impact of compre-
hensive care has been demonstrated by Soucie et al (2006) 
who found that hemophiliacs who had received care in a 
specialized hemophilia treatment center had a signiﬁ  cantly 
decreased risk of death. The impact of comprehensive care 
is further exempliﬁ  ed by the analysis of 164 patients treated 
at the International Haemophilia Training Centre at Bangkok 
with blood and blood components from 1971 to 2000. The 
estimated probability of survival beyond 13 years of age of 
patients with severe hemophilia increased from 0.85 during 
the ﬁ  rst decade of observation to 0.94 and 1 in the second 
and third decades (Chuansumrit et al 2004). The mortality 
rate fell from 30% to 14% and 5% over the three decades of 
observation. Despite the lack of treatment with high quality 
clotting factor concentrates in this center, the patients’ out-
come improved with the development of a comprehensive 
approach to management.
On behalf of the Italian Association of Hemophilia 
Centers (AICE), we are conducting a multicenter study to 
evaluate the health status and health-related quality of life 
(HR-QoL) of severely affected Italian hemophiliacs of 65 
years or older, recruited from Italian hemophilia centers 
(Tagliaferri et al 2006b). Another primary goal of the study is 
to provide information on whether or not there are differences 
in the global health status and HR-QoL between healthy 
elderly individuals and persons with hemophilia, who started 
their lives in the ﬁ  rst part of the last century when the avail-
ability and quality of treatment were poor. This study will 
also allow us to establish whether or not the burden of dis-
eases other than hemophilia (including cognitive impairment 
measured using instruments of geriatric medicine) is similar 
or different in cases and controls, and to understand which 
factors help people with severe hemophilia to cope with their 
disease and reach old age.
Clinical management of congenital 
hemophilia in elderly patients
Several clinical problems have become evident in hemo-
philiacs with increasing age. Hemophilia is associated 
with bleeding episodes, which often occur into the joints 
or muscles. Over time, recurrent bleeding into joints and 
muscles can cause permanent problems such as arthritis, 
chronic pain and joint damage resulting in poor control of 
balance and falls which ultimately worsen quality of life. 
Thus joint disease remains the leading cause of morbidity 
in those elderly hemophiliacs who had little or no access to 
prophylactic regimens and home treatment when they were 
younger. However, there is a paucity of studies investigating 
these aspects in hemophiliacs. An ongoing Australian study is 
evaluating the degree of joint-related dysfunction in persons 
with hemophilia older than 30 years and the feasibility of 
home exercise programs targeting balance training (Street 
2006). We have recently reported the case of a 72-year-old 
hemophiliac with severe joint bleeding in whom treatment 
was converted from ‘on-demand’ to a secondary prophylaxis 
regimen (Tagliaferri et al 2006a). The latter signiﬁ  cantly 
reduced the number of bleeding episodes in target joints, 
slowing the progression of the arthropathy and improving 
the patient’s perceived well-being. However, further studies, 
dealing with the approach to replacement therapy and the 
development of preventive physical therapy programs for 
elderly patients, are warranted.
Cardiovascular events are other clinical problems which 
increase with age. Attempts have been made to determine 
whether or not hemophilia protects from the development of 
atherosclerosis and cardiovascular events, but the results are 
contradictory. Studies of carotid and femoral artery intimal-
medial thickness as a surrogate of atherosclerosis burden 
showed that hemophilia does not protect from atherosclerosis 
(Sramek et al 2001). On the other hand, hemophiliacs have a 
decreased mortality rate due to ischemic heart disease, support-
ing the views that they are protected from arterial thrombosis 
(Sramek et al 2003). Cases of myocardial infarction are rare 
in hemophiliacs (Franchini 2004). Recently, Girolami et al 
(2006) reviewed reported cardiovascular events in patients 
with hemophilia A. Among the 42 cases published so far, nine 
occurred in individuals aged 65 or over. Analyzing the litera-
ture data, the authors concluded that the bleeding diathesis did 
not help to prevent the occurrence of arterial occlusions. Thus Clinical Interventions in Aging 2007:2(3) 364
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factors which are known to predispose to atherothrombosis 
(eg, hypercholesterolemia, smoking, diabetes, hypertension, 
aging) appear to overcome the coagulation defect. Concomi-
tant replacement therapy, especially with bypassing agents (ie, 
activated or non-activated prothrombin complex concentrates 
and recombinant activated factor VII), was identiﬁ  ed as having 
a predominant role in thrombotic manifestations in the majority 
of the cases (Aledort 2004).
A number of successful cardiovascular interventions 
in elderly hemophiliacs have been carried out (Bovenzi 
et al 2003; De Bels et al 2004). However, these cases raise 
the question of how to conduct anticoagulant therapy in 
such naturally anticoagulated patients. The management of 
cardiovascular events in elderly hemophiliacs necessarily 
differs from that of non-hemophilic patients. Thus, while 
the treatment of acute coronary syndromes in hemophiliacs 
requires a combination of antithrombotic and replacement 
therapies, thrombolytic therapy for myocardial infarctions is 
unjustiﬁ  ed in these patients due to the unacceptable risk of 
hemorrhage and should be substituted by alternative tech-
niques such as percutaneous coronary angioplasty (Mafrici 
et al 2003). Similarly, long-term anticoagulation should be 
avoided whenever possible by using, for example, a biopros-
thetic valve in valve surgery.
Elderly people with hemophilia are also at increased 
risk of chronic renal disease (Kulkarni et al 2003). This is 
probably due to chronic renal bleeding associated with the 
inherited coagulopathy which leads to structural renal abnor-
malities. Moreover, the concomitant presence of viral infec-
tions (eg, HIV and HCV) or exposure to nephrotoxic antiviral 
therapy may increase the incidence of renal dysfunction over 
time. Chronic renal disease is responsible for hypertension 
(Scully et al 2005), which is observed more frequently in 
elderly hemophiliacs than in the general population and is a 
risk factor not only for cardiac disease but also for cerebral 
hemorrhage.
Another important issue is the treatment of elderly 
patients with inhibitors. Although most inhibitors occur 
at a young age in patients with severe hemophilia, 
patients with mild hemophilia may develop inhibitors 
at an advanced age when they receive intensive factor 
VIII replacement therapy on the occasion of a surgical 
or invasive procedure for age-related problems such as 
prostatic hypertrophy, cardiovascular disease or cancer 
(Franchini et al 2006a). Indeed, there are some concerns 
on the use of bypassing agents in those patients considered 
at higher risk of developing thrombotic complications. 
However, Leebek et al (2006) have recently reported the 
safe and effective use of recombinant activated factor 
VII in three elderly patients with mild hemophilia A and 
high-titer inhibitors.
Management of acquired 
hemophilia in the elderly
General aspects of acquired hemophilia
Acquired hemophilia is an uncommon but potentially life-
threatening clinical syndrome characterized by the sudden 
onset of bleeding in patients with a negative family and 
personal history. Acquired hemophilia is caused by auto-
antibodies that, in the vast majority of cases, are directed 
against functional epitopes of factor VIII causing its neu-
tralization and/or accelerated clearance from the plasma 
(Delgado et al 2003).
The incidence of acquired hemophilia has been estimated 
to be 0.2–1.0 cases per 1 million persons per year, with 
a mortality rate estimated to be in the range of 8 to 22% 
(Franchini et al 2005a). Most hemorrhagic deaths occur 
within the ﬁ  rst few weeks after presentation. The age distri-
bution of autoantibodies is typically biphasic, with a small 
peak between 20 and 30 years (mainly postpartum inhibitors) 
and a larger peak in patients aged 68–80 years. Factor VIII 
inhibitors are distributed equally between sexes, although 
females predominate in the younger age group because of 
the association with pregnancy while males constitute the 
majority of patients with inhibitors over the age of 60 (Boggio 
and Green 2001). In approximately 50% of cases factor 
VIII autoantibodies occur in patients without concomitant 
diseases (spontaneous antibodies), and in nearly 10% of cases 
autoantibodies appear during the postpartum period, usually 
in primiparous women within 3 months of delivery (Green 
and Lechner 1981; Solymoss 1998). However, several other 
conditions and diseases (eg, autoimmune disorders, malig-
nancies and drugs) have been associated with the develop-
ment of factor VIII inhibitors (Bossi et al 1998).
The clinical picture of acquired hemophilia differs from 
that of “classical” hereditary hemophilia A. More than 80% 
of patients with factor VIII autoantibodies bleed into the skin, 
muscles or soft tissues (including retroperitoneal hematoma) 
and mucous membranes (eg, epistaxis, gastrointestinal and 
urological bleeds), whereas hemarthroses, a typical manifes-
tation of congenital factor VIII deﬁ  ciency, are unusual. Not 
rarely the hemorrhages in acquired hemophilia are serious 
or life-threatening, as in the case of cerebral hemorrhage or 
rapidly progressive retroperitoneal hematomas (Franchini 
et al 2005a).Clinical Interventions in Aging 2007:2(3) 365
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The diagnosis of acquired hemophilia is based on the 
demonstration of an isolated prolongation of the activated 
partial thromboplastin time, not corrected by incubating 
the patient’s plasma with equal volumes of normal plasma 
(mixing study), associated with low factor VIII levels and 
evidence of a factor VIII inhibitor (which can be titrated in 
Bethesda units (BU)/mL), in a patient with no previous per-
sonal or family history of bleeding (Cohen and Kessler 1996). 
Figure 1 reports the laboratory algorithm for the diagnosis 
of acquired hemophilia.
The treatment of acquired hemophilia is classically 
divided into two phases: acute and chronic. Acute phase 
treatment is focused on the bleeding symptoms (Ludlam et al 
1994). Efﬁ  cient hemostasis can be achieved with a variety 
of methods such as correction of FVIII deﬁ  ciency (plasma-
derived or recombinant FVIII concentrates, desmopressin) 
or bypassing the inhibitor (activated prothrombin complex 
concentrate [APCC], recombinant activated FVII [rFVIIa]) 
(Roberts 1999). The choice of antihemorrhagic therapy 
depends mainly on the site and the entity of the bleeding. In 
patients with a high titer of inhibitor and severe hemorrhage, 
extracorporeal removal of the autoantibody by therapeutic 
plasmapheresis or immunoadsorption of immunoglobulins 
to staphylococcal protein A may be used (Guillet 2001). 
The aim of the chronic phase of treatment is to eradicate 
the inhibitor, which is achieved by using immunosuppres-
sive agents including corticosteroids and such drugs as 
cyclophosphamide, azathioprine, 6-mercaptopurine and 
vincristine (Green et al 1993). High-dose immunoglobulins 
and cyclosporin have also been shown to be effective in 
acquired hemophilia and can be considered as second-line 
therapy for those patients who do not respond to standard 
immunosuppressive regimens (Schwartz et al 1995; Petrovic 
et al 2000). More recently, serotherapy with anti-CD20 
monoclonal antibody (rituximab) has been successfully used 
in immune disorders resulting from autoantibody formation, 
including acquired hemophilia (Wiestner et al 2002). Finally, 
immune tolerance induction protocols have been proposed for 
the eradication of autoantibodies against coagulation factors 
(Nemes and Pitlik 2000).
Clinical management of acquired 
hemophilia in elderly patients
As reported above, with the exception of post-partum cases, 
a large number of patients with acquired hemophilia are 
elderly.
Although acquired hemophilia is considered a very 
rare occurrence, its true incidence may be underestimated. 
Indeed, patients may be seen by several specialists and 
undergo dangerous invasive investigations and interventions 
before the correct diagnosis is made. The high mortality 
rate reported previously is in part related to a delay in the 
diagnosis. Besides misdiagnoses, acquired hemophilia may 
be underdiagnosed as many cases of clinically silent low 
titer inhibitors may be unrecognized unless patients undergo 
surgery or trauma.
In approximately 50% of the elderly patients with ac-
quired hemophilia, no underlying primary disorders are 
identiﬁ  ed (idiopathic forms), while most of the remaining 
cases are associated with autoimmune diseases or cancer, 
which increase with age (Hauser et al 1999; Yee et al 2000). 
The prognosis of acquired hemophilia in elderly patients is 
strongly linked to the associated primary disorder, which 
should be always searched for and, if possible, cured. The 
knowledge of the underlying disorder has important thera-
peutic consequences. Idiopathic cases with a low inhibitor 
titer and mild bleeding may be managed with desmopressin 
alone and may not require eradicating therapy but only a 
“watch and wait” strategy. Similarly, drug-induced inhibi-
tors may require nothing else than close observation, since 
these inhibitors tend to disappear spontaneously within a few 
months after drug discontinuation. On the other hand, it is 
unlikely that cases associated with autoimmune disorders will 
remit spontaneously and thus they require more aggressive 
eradication therapy with steroids, whether or not combined 
with cytotoxic agents such as cyclophosphamide (Franchini 
et al 2005b). However, particular care must be taken when 
using these agents in the elderly and the choice of drugs 
and dosages should be tailored to the individual patient’s 
age. An analysis of the data from the European Acquired 
Hemophilia Registry (Baudo et al 2004) showed that infec-
tions related to immunosuppressive therapy are the ﬁ  rst cause 
of death in patients with acquired hemophilia. Thus, less 
toxic agents should be preferred for inhibitor eradication in 
elderly patients. In this context, the use of rituximab seems 
to be particularly promising. We have recently reviewed the 
literature data on the use of rituximab in acquired hemophilia 
and have collected 50 cases, including many elderly patients 
(Franchini et al 2006b). Although most of the reports were 
isolated cases, there was a high%age of complete or partial 
responses (86%) when rituximab was used alone or in asso-
ciation with immunosuppressive therapy. Thus, if conﬁ  rmed 
by further controlled studies, this agent could be very useful 
in the management of such patients.
The presence of an underlying malignancy was associ-
ated with a poorer prognosis in a recent meta-analysis by Clinical Interventions in Aging 2007:2(3) 366
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Sudden onset of bleeding  
and
prolonged APTT with normal PT
 Mixing study 
(APTT on a mixture of 1 volume 
patient plasma and 1 volume 
normal plasma. Incubation 2 
hours at 37 °C) 
APTT mix prolonged 
Assay of clotting factors  
of the intrinsic pathway   
APTT mix normal 
 Specific deficiency of 
one clotting factor of 
the intrinsic pathway 
Specific inhibitor quantification 
(Bethesda assay) 
DIAGNOSIS OF
ACQUIRED HEMOHILIA 
Reduction of one clotting factor 
Figure 1 Diagnostic algorithm of acquired hemophilia. 
Abbreviations:   APTT,  activated partial thromboplastin time; PT,  prothrombin time.Clinical Interventions in Aging 2007:2(3) 367
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Delgado et al (2003). However, Sallah et al (2001), in a 
previous review of literature data on 41 cases of patients with 
cancer-associated factor VIII inhibitors, including patients 
with solid and hematologic malignancies, found a 70% rate 
of complete responses to treatment of the inhibitor. Low 
titer inhibitors associated with early stage tumors were more 
likely to disappear after treatment than high titer inhibitors 
and the eradication of autoantibody was associated with a 
higher overall survival. The same authors also observed that 
22% of responders achieved complete remission after treatment 
of the cancer. On the basis of this high response rate, it appears 
that the treatment of the primary malignancy in patients with 
cancer-associated factors VIII inhibitors is of great importance, 
because this facilitates eradication of the antibody. The presence 
of an underlying cancer is not a contraindication to the use of im-
munosuppressive therapy aimed at eradicating the autoantibody, 
so that these patients should be treated in the same manner as 
other patients with acquired hemophilia.
Although only a few thrombotic adverse events have been 
recorded in patients with acquired hemophilia following the 
use of bypassing agents (Guillet et al 2002; Roberts et al 2004), 
particular care should be exercised when these drugs are used 
in elderly patients who should be monitored not only for clini-
cal evidence of hemorrhage but also for the possible onset of 
thrombotic complications. Concomitant cardiovascular diseases 
should be ruled out before using desmopressin in elderly patients 
with congenital or acquired hemophilia (Mannucci 1997).
Conclusions
With their greatly prolonged life expectancy, persons with 
congenital hemophilia are now developing medical and sur-
gical conditions previously not seen in this group. The new 
challenge for physicians in hemophilia centers is to provide 
optimal care for this aging population of patients. Their 
optimal management requires a hemophilia team with close 
cooperation among physicians from different specialties such 
as hematology, oncology, cardiology, and nephrology.
The prognosis of acquired hemophilia in elderly people 
depends on the underlying primary disorder. Particular 
care must be taken when choosing the inhibitor eradication 
regimen, which should be tailored to the patient’s age.
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